BRIEF-Azurrx Biopharma Inc Signed An Exclusive Worldwide Licensing Agreement With First Wave Bio, Inc.

Reuters

04 Jan 2021

Jan 4 (Reuters) - AzurRx BioPharma Inc :

* AZURRX BIOPHARMA INC - SIGNED AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH FIRST WAVE BIO, INC.

* AZURRX BIOPHARMA INC - AGREEMENT FOR USE OF FIRST WAVE'S PATENTED AND PROPRIETARY ORAL AND RECTAL FORMULATIONS OF NICLOSAMIDE

* AZURRX BIOPHARMA INC - AZURRX IS ON TRACK TO REPORT TOP-LINE DATA FOR ITS TWO PHASE 2 MS1819 CLINICAL TRIALS IN FIRST AND SECOND QUARTERS OF 2021

* AZURRX BIOPHARMA INC - CO ANTICIPATES INITIATING BOTH PHASE 2 COVID-19 GI INFECTION TRIAL AND A PHASE 1B/2A ICI-AC TRIAL IN FIRST HALF OF 2021

* AZURRX BIOPHARMA INC - FIRST WAVE WILL RECEIVE AN UPFRONT PAYMENT OF $10.25 MILLION IN CASH PAYABLE $9.0 MILLION AT CLOSING AND $1.25 MILLION BY JUNE 30, 2021

* AZURRX BIOPHARMA INC - FIRST WAVE TO ALSO RECEIVE $3.0 MILLION OF CONVERTIBLE JUNIOR PREFERRED STOCK, WHICH SHALL BE CONVERTIBLE INTO COMMON STOCK

* AZURRX BIOPHARMA INC - FIRST WAVE TO ALSO RECEIVE UP TO $74.0 MILLION IN POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONES

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2100664378"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2100664378\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2100664378?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-01-04 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2100664378","market":"us","top_or_hot":-1,"title":"BRIEF-Azurrx Biopharma Inc Signed An Exclusive Worldwide Licensing Agreement With First Wave Bio, Inc.","media":"Reuters","content":"<html><body><p>Jan 4 (Reuters) - AzurRx BioPharma Inc   :</p><p>   * AZURRX BIOPHARMA INC - SIGNED AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH FIRST WAVE BIO, INC.</p><p>   * AZURRX BIOPHARMA INC - AGREEMENT FOR USE OF FIRST WAVE'S PATENTED AND PROPRIETARY ORAL AND RECTAL FORMULATIONS OF NICLOSAMIDE</p><p>   * AZURRX BIOPHARMA INC - AZURRX IS ON TRACK TO REPORT TOP-LINE DATA FOR ITS TWO PHASE 2 MS1819 CLINICAL TRIALS IN FIRST AND SECOND QUARTERS OF 2021</p><p>   * AZURRX BIOPHARMA INC - CO ANTICIPATES INITIATING BOTH PHASE 2 COVID-19 GI INFECTION TRIAL AND A PHASE 1B/2A ICI-AC TRIAL IN FIRST HALF OF 2021</p><p>   * AZURRX BIOPHARMA INC - FIRST WAVE WILL RECEIVE AN UPFRONT PAYMENT OF $10.25 MILLION IN CASH PAYABLE $9.0 MILLION AT CLOSING AND $1.25 MILLION BY JUNE 30, 2021</p><p>   * AZURRX BIOPHARMA INC - FIRST WAVE TO ALSO RECEIVE $3.0 MILLION OF CONVERTIBLE JUNIOR PREFERRED STOCK, WHICH SHALL BE CONVERTIBLE INTO COMMON STOCK</p><p>   * AZURRX BIOPHARMA INC - FIRST WAVE TO ALSO RECEIVE UP TO $74.0 MILLION IN POTENTIAL DEVELOPMENT &amp; COMMERCIAL MILESTONES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Azurrx Biopharma Inc Signed An Exclusive Worldwide Licensing Agreement With First Wave Bio, Inc.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Azurrx Biopharma Inc Signed An Exclusive Worldwide Licensing Agreement With First Wave Bio, Inc.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-01-04 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 4 (Reuters) - AzurRx BioPharma Inc   :</p><p>   * AZURRX BIOPHARMA INC - SIGNED AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH FIRST WAVE BIO, INC.</p><p>   * AZURRX BIOPHARMA INC - AGREEMENT FOR USE OF FIRST WAVE'S PATENTED AND PROPRIETARY ORAL AND RECTAL FORMULATIONS OF NICLOSAMIDE</p><p>   * AZURRX BIOPHARMA INC - AZURRX IS ON TRACK TO REPORT TOP-LINE DATA FOR ITS TWO PHASE 2 MS1819 CLINICAL TRIALS IN FIRST AND SECOND QUARTERS OF 2021</p><p>   * AZURRX BIOPHARMA INC - CO ANTICIPATES INITIATING BOTH PHASE 2 COVID-19 GI INFECTION TRIAL AND A PHASE 1B/2A ICI-AC TRIAL IN FIRST HALF OF 2021</p><p>   * AZURRX BIOPHARMA INC - FIRST WAVE WILL RECEIVE AN UPFRONT PAYMENT OF $10.25 MILLION IN CASH PAYABLE $9.0 MILLION AT CLOSING AND $1.25 MILLION BY JUNE 30, 2021</p><p>   * AZURRX BIOPHARMA INC - FIRST WAVE TO ALSO RECEIVE $3.0 MILLION OF CONVERTIBLE JUNIOR PREFERRED STOCK, WHICH SHALL BE CONVERTIBLE INTO COMMON STOCK</p><p>   * AZURRX BIOPHARMA INC - FIRST WAVE TO ALSO RECEIVE UP TO $74.0 MILLION IN POTENTIAL DEVELOPMENT &amp; COMMERCIAL MILESTONES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2100664378","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2100664378","pubTimestamp":1609763808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 4 (Reuters) - AzurRx BioPharma Inc   :   * AZURRX BIOPHARMA INC - SIGNED AN EXCLUSIVE WORLDWIDE ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BRIEF-Azurrx生物制药公司与First Wave Bio，Inc.签署了全球独家许可协议。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZRX":0.9},"content_text":"Jan 4 (Reuters) - AzurRx BioPharma Inc   :   * AZURRX BIOPHARMA INC - SIGNED AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH FIRST WAVE BIO, INC.   * AZURRX BIOPHARMA INC - AGREEMENT FOR USE OF FIRST WAVE'S PATENTED AND PROPRIETARY ORAL AND RECTAL FORMULATIONS OF NICLOSAMIDE   * AZURRX BIOPHARMA INC - AZURRX IS ON TRACK TO REPORT TOP-LINE DATA FOR ITS TWO PHASE 2 MS1819 CLINICAL TRIALS IN FIRST AND SECOND QUARTERS OF 2021   * AZURRX BIOPHARMA INC - CO ANTICIPATES INITIATING BOTH PHASE 2 COVID-19 GI INFECTION TRIAL AND A PHASE 1B/2A ICI-AC TRIAL IN FIRST HALF OF 2021   * AZURRX BIOPHARMA INC - FIRST WAVE WILL RECEIVE AN UPFRONT PAYMENT OF $10.25 MILLION IN CASH PAYABLE $9.0 MILLION AT CLOSING AND $1.25 MILLION BY JUNE 30, 2021   * AZURRX BIOPHARMA INC - FIRST WAVE TO ALSO RECEIVE $3.0 MILLION OF CONVERTIBLE JUNIOR PREFERRED STOCK, WHICH SHALL BE CONVERTIBLE INTO COMMON STOCK   * AZURRX BIOPHARMA INC - FIRST WAVE TO ALSO RECEIVE UP TO $74.0 MILLION IN POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONESSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}